← All trials
NCT05536284
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- May 20, 2022
- Completion date
- Aug 16, 2022
- First posted
- Sep 10, 2022
- Last posted
- Sep 10, 2022
- Enrollment
- 127
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Damanhour UniversityLead sponsor
- Alexandria UniversityCollaborator
- Alexandria UniversityStudy chair
- Damanhour UniversityOverall official - principal investigator
- Damanhour UniversityStudy chair
- Damanhour UniversityStudy chair
- Damanhour UniversityStudy director
- Damanhour UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.